One important metric to look for in a stock is an 80 or higher Relative Strength Rating. AstraZeneca ADR now clears that ...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...
In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...
22h
Investor's Business Daily on MSNAstraZeneca Stock Nears Buy Point After Long Run In Declining MarketAstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...
STORY: Stubborn inflation and President Donald Trump’s trade policies have rekindled fears of stagflation, a troubling ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...
21h
GlobalData on MSNVivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
20h
MedPage Today on MSNNCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown ContinuesThe American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
Two British diplomats expelled in a spying row. A blistering statement from Russia's foreign intelligence service calling ...
She would have explained that there had been 14 documented deaths linked with Covid vaccines across Australia, where more than 60 million doses have been administered. Thirteen of those deaths were ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results